Cargando…
Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents
To reduce 5-fluorouracil (5-FU)-induced serious toxicities without loss of antitumor activity, we have developed DFP-11207, a novel fluoropyrimidine, which consists of 1-ethoxymethyl-5-fluorouracil (EM-FU; a precursor form of 5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP; an inhibitor of 5-FU degradat...
Autores principales: | Fukushima, Masakazu, Iizuka, Kenzo, Jin, Cheng, Zhang, Chun, Hong, Mei, Eshima, Kiyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472421/ https://www.ncbi.nlm.nih.gov/pubmed/28652707 http://dx.doi.org/10.2147/DDDT.S128420 |
Ejemplares similares
-
Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model
por: Iizuka, Kenzo, et al.
Publicado: (2018) -
Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C(max) and improved tolerability, in patients with solid tumors
por: Ajani, Jaffer A., et al.
Publicado: (2020) -
A novel intraperitoneal therapy for gastric cancer with DFP‐10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model
por: Ando, Hidenori, et al.
Publicado: (2019) -
HCC diagnosis DFP report
Publicado: (2021) -
Neuroendocrine neoplasm DFP report
Publicado: (2021)